These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24763786)

  • 1. Lower risk for body weight gain and better control of appetite after switching risperidone to paliperidone in a schizoaffective patient.
    Hou YC; Lai CH
    J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(2):E36-7. PubMed ID: 24763786
    [No Abstract]   [Full Text] [Related]  

  • 2. Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone.
    Teng PR; Lane HY
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E16-7. PubMed ID: 22231327
    [No Abstract]   [Full Text] [Related]  

  • 3. Improvement in psychotic symptoms and social functioning after augmentation of paliperidone with clozapine in a patient with schizoaffective disorder.
    Hou YC
    J Neuropsychiatry Clin Neurosci; 2014; 26(1):E26. PubMed ID: 24515699
    [No Abstract]   [Full Text] [Related]  

  • 4. Risperidone/paliperidone induced neutropenia and lymphopenia.
    Raj V; Druitt T; Purushothaman S; Dunsdon J
    Aust N Z J Psychiatry; 2013 Mar; 47(3):291-2. PubMed ID: 22984110
    [No Abstract]   [Full Text] [Related]  

  • 5. Rabbit syndrome following discontinuation of paliperidone in a patient with schizoaffective disorder.
    Liang CS; Yang FW; Huang YC
    J Clin Psychopharmacol; 2012 Oct; 32(5):720-1. PubMed ID: 22926613
    [No Abstract]   [Full Text] [Related]  

  • 6. [Efficacy, tolerability and safety of paliperidone extended-release in the treatment of schizophrenia and schizoaffective disorder].
    Bellantuono C; Santone G
    Riv Psichiatr; 2012; 47(1):5-20. PubMed ID: 22358213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Manic symptoms during a switch from risperidone to paliperidone: a case report.
    Yang FW; Liang CS
    J Neuropsychiatry Clin Neurosci; 2011; 23(3):E29. PubMed ID: 21948917
    [No Abstract]   [Full Text] [Related]  

  • 8. QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone.
    Suzuki Y; Fukui N; Watanabe J; Ono S; Sugai T; Tsuneyama N; Saito M; Inoue Y; Someya T
    Hum Psychopharmacol; 2012 Jan; 27(1):39-42. PubMed ID: 22144033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to paliperidone.
    Hsu WY; Chiu NY
    J Clin Psychopharmacol; 2013 Oct; 33(5):712-3. PubMed ID: 23899637
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolerability of paliperidone: a meta-analysis of randomized, controlled trials.
    Harrington CA; English C
    Int Clin Psychopharmacol; 2010 Nov; 25(6):334-41. PubMed ID: 20706126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paliperidone-induced leukopenia and neutropenia: a case report.
    Kim JN; Lee BC; Choi IG; Jon DI; Jung MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Jan; 35(1):284-5. PubMed ID: 20920543
    [No Abstract]   [Full Text] [Related]  

  • 12. Paliperidone-induced tardive dystonia: a case report.
    Havaki-Kontaxaki B; Karaiskos D; Pappa D; Papadimitriou GN
    J Neuropsychiatry Clin Neurosci; 2013; 25(2):E51. PubMed ID: 23686064
    [No Abstract]   [Full Text] [Related]  

  • 13. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite.
    Melkersson KI
    Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remission of drug-induced hepatitis after switching from risperidone to paliperidone.
    Paulzen M; Orfanos S; Gründer G
    Am J Psychiatry; 2010 Mar; 167(3):351-2. PubMed ID: 20194492
    [No Abstract]   [Full Text] [Related]  

  • 15. Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial.
    Wessels AM; Pollock BG; Anyama NG; Schneider LS; Lieberman JA; Marder SR; Bies RR
    J Clin Psychopharmacol; 2010 Dec; 30(6):683-7. PubMed ID: 21105282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder.
    Canuso CM; Lindenmayer JP; Kosik-Gonzalez C; Turkoz I; Carothers J; Bossie CA; Schooler NR
    J Clin Psychiatry; 2010 May; 71(5):587-98. PubMed ID: 20492853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paliperidone-induced obsessive symptoms.
    Paparrigopoulos T; Tzavellas E; Karaiskos D; Liappas I
    J Neuropsychiatry Clin Neurosci; 2011; 23(2):E46. PubMed ID: 21677227
    [No Abstract]   [Full Text] [Related]  

  • 18. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.
    Berwaerts J; Cleton A; Rossenu S; Talluri K; Remmerie B; Janssens L; Boom S; Kramer M; Eerdekens M
    J Psychopharmacol; 2010 Jul; 24(7):1011-8. PubMed ID: 19825908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choreatic symptoms during and after treatment with paliperidone and escitalopram.
    Hüther R; Gebhart C; Mirisch S; Bäuml J; Förstl H
    Pharmacopsychiatry; 2008 Sep; 41(5):203-4. PubMed ID: 18763225
    [No Abstract]   [Full Text] [Related]  

  • 20. Catatonia and encephalopathy associated with paliperidone palmitate.
    Coffey MJ
    J Clin Psychopharmacol; 2012 Apr; 32(2):284-5. PubMed ID: 22388156
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.